XOMA

XOMA Corporation · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website xoma.com
Employees(FY) 12
ISIN US98419J2069

Performance

+7.68%

1W

+4.63%

1M

+10.29%

3M

+72.36%

6M

+37.89%

YTD

+19.26%

1Y

Profile

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.

Advanced Technical Analysis

Technical Analysis of XOMA 2024-05-10

Overview:

In analyzing the technical indicators for XOMA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Indicators...

See more ...

Recent News & Updates

2024-05-13 19:30
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ(Globenewswire)
2024-05-10 03:18
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss(Yahoo Finance)
2024-05-09 01:55
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-08 20:00
Xoma: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-08 19:30
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities(Globenewswire)
2024-05-06 22:00
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release(Zacks)
2024-04-29 19:30
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2%(Globenewswire)
2024-04-24 19:30
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)(Globenewswire)
2024-04-23 21:00
Actym Therapeutics Appoints Thomas Smart as CEO(Prnewswire)
2024-04-02 21:00
XOMA Corporation Announces Closing of Tender Offer(Globenewswire)
2024-03-20 19:30
XOMA Declares Quarterly Preferred Stock Dividends(Globenewswire)
2024-03-19 04:05
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.(Globenewswire)
2024-03-07 23:53
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-07 19:12
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023(Yahoo Finance)
2024-03-07 18:52
Xoma: Q4 Earnings Snapshot(Yahoo Finance)
2024-03-07 18:30
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value(Globenewswire)
2024-02-27 18:30
XOMA to Present at Upcoming Investor Conferences in March(Globenewswire)
2024-02-15 19:00
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right(Globenewswire)
2024-01-17 19:30
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition(Globenewswire)
2024-01-11 03:05
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx(Globenewswire)
2024-01-07 18:30
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors(Globenewswire)
2024-01-01 18:30
XOMA Announces Stock Repurchase Program of up to $50 Million(Globenewswire)
2023-12-19 18:30
XOMA Declares Quarterly Preferred Stock Dividends(Globenewswire)
2023-12-18 18:30
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties(Globenewswire)
2023-11-06 18:50
Xoma: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-06 18:30
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value(Globenewswire)
2023-10-30 19:30
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)(Globenewswire)
2023-09-24 19:30
XOMA Declares Quarterly Preferred Stock Dividends(Yahoo Finance)
2023-09-05 19:30
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-31 10:43
10 Stocks That Are About To Explode(Yahoo Finance)

Page 1 of 4

previousnext